Keymed Biosciences, Inc. (HK:2162) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Keymed Biosciences Inc. has announced the approval of their new drug, Stapokibart, by China’s National Medical Products Administration for treating moderate-to-severe atopic dermatitis in adults. This first domestically manufactured IL-4R α antibody drug showed promising results in Phase III clinical trials, meeting primary endpoints and exhibiting a good safety profile. However, the company cautions shareholders that there’s no guarantee of successful commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.